ArticleNeural regeneration research2018
Amnion epithelial cells - a novel therapy for ischemic stroke?
Article in Neural regeneration research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Human amniotic epithelial stem cells, a potential therapeutic approach for diabetes and its related complications.Human cell · 2025Review
- Predictive and prognostic values of serum C1q/tumor necrosis factor-related protein 9 for first-ever ischemic stroke.Frontiers in neurology · 2025Article
- Review
- A swift expanding trend of extracellular vesicles in spinal cord injury research: a bibliometric analysis.Journal of nanobiotechnology · 2023Review
- The central role of peripheral inflammation in ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Review
- Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT).Frontiers in neuroscience · 2023Article
- Serum CTRP9 and high-molecular weight adiponectin are associated with ischemic stroke.BMC neurology · 2022Article
- Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases.Human cell · 2022Review
- Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.Stem cell research & therapy · 2022Review
- Review
- Mesenchymal Stem/Stromal Cell Therapy in Blood-Brain Barrier Preservation Following Ischemia: Molecular Mechanisms and Prospects.International journal of molecular sciences · 2021Review
- Targeting Brain-spleen Crosstalk After Stroke: New Insights Into Stroke Pathology and Treatment.Current neuropharmacology · 2021Review
- Article
- Systemic treatment with human amnion epithelial cells after experimental traumatic brain injury.Brain, behavior, & immunity - health · 2020Article
- Harnessing the anti-inflammatory properties of stem cells for transplant therapy in hemorrhagic stroke.Brain hemorrhages · 2020Article
- Neuroprotective mechanism of TMP269, a selective class IIA histone deacetylase inhibitor, after cerebral ischemia/reperfusion injury.Neural regeneration research · 2020Article
- The spleen may be an important target of stem cell therapy for stroke.Journal of neuroinflammation · 2019Review
- Therapeutic Potential of Human Amniotic Epithelial Cells on Injuries and Disorders in the Central Nervous System.Stem cells international · 2019Review
- Article
- A Human Amniotic Membrane Plug to Treat Persistent Macular Hole.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells (hAECs), which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days post-stroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that hAECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.